Brain metastases in HER2-positive metastatic breast cancer patients who received chemotherapy with or without trastuzumab

被引：0
|
作者：
Muhammet Ali Kaplan
Hamza Ertugrul
Ugur Firat
Mehmet Kucukoner
Ali İnal
Zuhat Urakci
Zafer Pekkolay
Abdurrahman Isikdogan
机构：
[1] Dicle University School of Medicine,Department of Medical Oncology
[2] Dicle University School of Medicine,Department of Internal Medicine
[3] Dicle University School of Medicine,Department of Pathology
来源：
Breast Cancer | 2015年 / 22卷
关键词：
Breast cancer; Brain metastasis; Trastuzumab;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：503 / 509
页数：6
相关论文
共 50 条
  • [31] Beyond trastuzumab: novel therapeutic strategies in HER2-positive metastatic breast cancer
    Tsang, R. Y.
    Finn, R. S.
    BRITISH JOURNAL OF CANCER, 2012, 106 (01) : 6 - 13
  • [32] When should trastuzumab be stopped after achieving complete response in HER2-positive metastatic breast cancer patients?
    Beda, Manuela
    Basso, Umberto
    Ghiotto, Cristina
    Monfardini, Silvio
    TUMORI JOURNAL, 2007, 93 (05): : 491 - 492
  • [33] Trastuzumab combined with chemotherapy for the treatment of HER2-positive metastatic breast cancer: Pivotal trial data
    Eiermann, W
    ANNALS OF ONCOLOGY, 2001, 12 : 57 - 62
  • [34] Systemic Treatment Options for HER2-Positive Breast Cancer Patients with Brain Metastases beyond Trastuzumab: A Literature Review
    Laakmann, Elena
    Mueller, Volkmar
    Schmidt, Marcus
    Witzel, Isabell
    BREAST CARE, 2017, 12 (03) : 168 - 171
  • [35] Optimizing the Management of Metastatic HER2-Positive Breast Cancer
    Goel S.
    Tolaney S.
    Current Breast Cancer Reports, 2015, 7 (4) : 190 - 202
  • [36] Efficacy of trastuzumab in unselected patients with HER2-positive metastatic breast cancer: a retrospective analysis
    Collova, Elena
    Ferzi, Antonella
    Scandurra, Giuseppa
    Aurilio, Gaetano
    Torri, Valter
    Porcu, Luca
    Sano, Maria Vita
    Taibi, Eleonora
    Foglietta, Jennifer
    Generali, Daniele
    Andreis, Daniele
    Dazzani, Maria Chiara
    Bramati, Annalisa
    Marcon, Ilaria
    Atzori, Francesco
    Cinieri, Saverio
    Tondulli, Luca
    Grasso, Donatalla
    Nole, Franco
    Petrella, Maria Cristina
    Gori, Stefania
    La Verde, Nicla
    TUMORI, 2014, 100 (04) : 426 - 431
  • [37] Trastuzumab as first-line therapy in HER2-positive metastatic breast cancer patients
    Del Mastro, Lucia
    Lambertini, Matteo
    Bighin, Claudia
    Levaggi, Alessia
    D'Alonzo, Alessia
    Giraudi, Sara
    Pronzato, Paolo
    EXPERT REVIEW OF ANTICANCER THERAPY, 2012, 12 (11) : 1391 - 1405
  • [38] Pertuzumab in combination with trastuzumab and docetaxel for HER2-positive metastatic breast cancer
    Kawajiri, Hidemi
    Takashima, Tsutomu
    Kashiwagi, Shinichiro
    Noda, Satoru
    Onoda, Naoyoshi
    Hirakawa, Kosei
    EXPERT REVIEW OF ANTICANCER THERAPY, 2015, 15 (01) : 17 - 26
  • [39] Management of patients with HER2-positive metastatic breast cancer after trastuzumab deruxtecan failure
    Antonarelli, G.
    Corti, C.
    Salimbeni, B. T.
    Tarantino, P.
    Zagami, P.
    Marra, A.
    Trapani, D.
    Tolaney, S.
    Cortes, J.
    Curigliano, G.
    ESMO OPEN, 2023, 8 (04)
  • [40] Prevention strategies for brain metastases from HER2-positive breast cancer
    Le Tourneau, Christophe
    BULLETIN DU CANCER, 2011, 98 (04) : 445 - 449
12345